BTIG analyst Julian Harrison raised the firm’s price target on Oruka Therapeutics (ORKA) to $63 from $56 and keeps a Buy rating on the shares after its Q3 results. The firm remains focused on the upcoming ORKA-002 Phase 1 HV PK data expected around 2025-end, noting that the data should confirm ORKA-002 with best-in-class half-life that could support commercially relevant improvements vs. Bimzelx, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics initiated with a Buy at Jefferies
- Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating
- Oruka Therapeutics reports Q3 EPS (55c), consensus (52c)
- ORKA Earnings this Week: How Will it Perform?
- Oruka Therapeutics’ Promising Psoriasis Study: What Investors Need to Know